Back to discover
Disease

Pseudotumor Cerebri

Late-stage therapeutic developmentEmerging research
2
Publications
1
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).

Clinical trials

1 sponsors · 0 new · 1 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
1
All trials
0
Active
1
Late-stage
1
Completed

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182023
Major themes2
  • Pseudotumor Cerebri2
  • Headache1
Leading journals2
  • Journal of neurology, neurosurgery, and psychiatry1
  • The journal of headache and pain1
Leading researchers8
  • Bsteh G1
  • Burdon MA1
  • Chavda SV1
  • Davies B1
  • Digre K1
  • Edwards J1
  • Harreiter J1
  • Hassan-Smith G1
Affiliations (unnormalised)6
  • Alder Hey Children's NHS Foundation Trust1
  • Centre for Endocrinology1
  • Children's Hospital of Philadelphia and Hospital of the University of Pennsylvania1
  • Comprehensive Center for Clinical Neurosciences1
  • Danish Headache Center1
  • Gloucestershire Hospitals NHS Foundation Trust1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition marked by raised intracranial pressure and characterized clinically by HEADACHES; NAUSEA; PAPILLEDEMA, peripheral constriction of the visual fields, transient visual obscurations, and pulsatile TINNITUS. OBESITY is frequently associated with this condition, which primarily affects women between 20 and 44 years of age. Chronic PAPILLEDEMA may lead to optic nerve injury (see OPTIC NERVE DISEASES) and visual loss (see BLINDNESS).

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.